NCT02858310 2026-03-09
E7 TCR T Cells for Human Papillomavirus-Associated Cancers
National Institutes of Health Clinical Center (CC)
Phase 1/2 Completed
Clinical Trials
31 trialsNCT04426669 2026-02-23
A Study of Metastatic Gastrointestinal Cancers Treated With Tumor Infiltrating Lymphocytes in Which the Gene Encoding the Intracellular Immune Checkpoint CISH Is Inhibited Using CRISPR Genetic Engineering
Intima Bioscience, Inc.
Phase 1/2 Completed
NCT03318900 2024-11-07
T-Cell Infusion, Aldesleukin, and Utomilumab in Treating Patients With Recurrent Ovarian Cancer
M.D. Anderson Cancer Center
Phase 1/2 Completed
NCT03296137 2024-10-26
Adoptive Cell Therapy Across Cancer Diagnoses
Herlev Hospital
Phase 1/2 Completed
NCT01740557 2024-10-08
Genetically Modified Therapeutic Autologous Lymphocytes Followed by Aldesleukin in Treating Patients With Stage III or Metastatic Melanoma
M.D. Anderson Cancer Center
Phase 1/2 Completed
NCT06152367 2023-11-30
Immunization With Autologous Dendritic Cells and Tumor Lysates in Melanoma Patients
University of Chile
Phase 1/2 Completed
NCT01823198 2023-11-07
Donor Natural Killer Cells and Donor Stem Cell Transplant in Treating Patients With High Risk Myeloid Malignancies
M.D. Anderson Cancer Center
Phase 1/2 Completed
NCT02111850 2022-03-29
T Cell Receptor Immunotherapy Targeting MAGE-A3 for Patients With Metastatic Cancer Who Are HLA-DP0401 Positive
National Institutes of Health Clinical Center (CC)
Phase 1/2 Completed
NCT00924326 2022-01-12
CAR T Cell Receptor Immunotherapy for Patients With B-cell Lymphoma
National Institutes of Health Clinical Center (CC)
Phase 1/2 Completed
NCT02379195 2020-01-22
Peginterferon and TIL Therapy for Metastatic Melanoma
Herlev Hospital
Phase 1/2 Completed
NCT01550367 2020-01-02
Study of Hydroxychloroquine and Aldesleukin in Renal Cell Carcinoma Patients (RCC)
University of Pittsburgh
Phase 1/2 Completed
NCT00303667 2017-12-28
Donor Natural Killer Cells and Aldesleukin in Treating Patients w/High Risk AML Undergoing Donor Stem Cell Transplant
Masonic Cancer Center, University of Minnesota
Phase 1/2 Completed
NCT02280811 2017-09-06
T Cell Receptor Immunotherapy Targeting HPV-16 E6 for HPV-Associated Cancers
National Institutes of Health Clinical Center (CC)
Phase 1/2 Completed
NCT00062036 2017-07-02
Cyclophosphamide and Fludarabine Followed By Interleukin-2 Gene-Modified Tumor Infiltrating Lymphocytes in Treating Patients With Metastatic Melanoma
National Institutes of Health Clinical Center (CC)
Phase 1/2 Completed
NCT00871481 2017-04-19
Laboratory-Treated T Cells and Ipilimumab in Treating Patients With Metastatic Melanoma
Fred Hutchinson Cancer Center
Phase 1/2 Completed
NCT00052520 2017-03-29
Biological Therapy in Treating Patients With Advanced Myelodysplastic Syndrome, Acute or Chronic Myeloid Leukemia, or Acute Lymphoblastic Leukemia Who Are Undergoing Stem Cell Transplantation
Fred Hutchinson Cancer Center
Phase 1/2 Completed
NCT01592045 2015-09-23
ch14.18 Pharmacokinetic Study in High-risk Neuroblastoma
United Therapeutics
Phase 1/2 Completed
NCT00937625 2015-08-18
T-cell Based Immunotherapy for of Melanoma
Herlev Hospital
Phase 1/2 Completed
NCT00003585 2013-12-10
Biological Therapy Plus Chemotherapy in Treating Patients With Metastatic or Recurrent Kidney Cancer
University of New Mexico
Phase 1/2 Completed
NCT00003356 2013-10-16
Rituximab Plus Interleukin-2 in Treating Patients With Lymphoma
University of Rochester
Phase 1/2 Completed
NCT00588913 2013-07-10
Adoptive Immunotherapy, Aldesleukin, and Zoledronate in Treating Patients With Stage IV Kidney Cancer and Lung Metastases
National Cancer Institute (NCI)
Phase 1/2 Completed
NCT00019214 2013-06-20
Vaccine Therapy With or Without Interleukin-2 in Treating Patients With Metastatic Melanoma
National Cancer Institute (NCI)
Phase 1/2 Completed
NCT00019591 2013-06-20
Vaccine Therapy With or Without Interleukin-2 in Treating Patients With Locally Advanced or Metastatic Colorectal Cancer
National Cancer Institute (NCI)
Phase 1/2 Completed
NCT00058279 2013-06-20
Monoclonal Antibody Therapy and Interleukin-2 in Treating Patients With Metastatic Melanoma
National Cancer Institute (NCI)
Phase 1/2 Completed
NCT00003229 2013-03-25
Vaccine Therapy in Treating Patients With Metastatic Melanoma Who Are Undergoing Surgery for Lymph Node and Tumor Removal
Duke University
Phase 1/2 Completed
NCT00002925 2012-11-30
Combination Chemotherapy Plus PSC 833 Followed by Interleukin-2 in Treating Patients With Acute Myelogenous Leukemia
National Cancer Institute (NCI)
Phase 1/2 Completed
NCT00002681 2011-06-10
Monoclonal Antibody Plus Interleukin-2 in Treating Patients With Leukemia or Lymphoma
Roger Williams Medical Center
Phase 1/2 Completed
NCT00248430 2010-09-21
Donor White Blood Cell Infusions and Interleukin-2 in Treating Patients Who Are Undergoing an Autologous Stem Cell Transplant for Relapsed Advanced Lymphoid Cancer
Fred Hutchinson Cancer Center
Phase 1/2 Completed
NCT00002786 2010-05-10
Biological Therapy in Treating Patients With Metastatic Melanoma
Fred Hutchinson Cancer Center
Phase 1/2 Completed
NCT00197912 2010-04-26
Dendritic Cell Based Therapy of Malignant Melanoma
Herlev Hospital
Phase 1/2 Completed
NCT00005802 2010-04-02
Chemotherapy Followed by Donor White Blood Cells Plus Interleukin-2 in Treating Patients With Acute Myeloid or Lymphocytic Leukemia
Fred Hutchinson Cancer Center
Phase 1/2 Completed